Hftril 100 Tablet contains a combination of Sacubitril (49mg) and Valsartan (51mg), formulated for the management of heart failure with reduced ejection fraction (HFrEF). Sacubitril is a neprilysin inhibitor that enhances the levels of natriuretic peptides, promoting vasodilation, natriuresis, and diuresis, thereby reducing cardiac workload and improving cardiac function. Valsartan, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation and decreased blood pressure. The synergistic action of these agents helps in reducing the risk of cardiovascular death and hospitalization due to heart failure. Hftril 100 is indicated for adult patients with chronic heart failure, particularly those who remain symptomatic despite optimal treatment with standard therapies such as ACE inhibitors or ARBs alone. The medication should be administered under strict medical supervision, with dosage adjustments based on renal function, blood pressure, and electrolyte levels. Common adverse effects may include hypotension, hyperkalemia, renal impairment, and dizziness. Contraindications include history of angioedema related to previous ACE inhibitor or ARB therapy and concomitant use with ACE inhibitors. Regular monitoring is essential to ensure therapeutic efficacy and safety.